Maternus-Kliniken Aktiengesellschaft

DB:MAK Stock Report

Market Cap: €37.7m

Maternus-Kliniken Past Earnings Performance

Past criteria checks 0/6

Maternus-Kliniken's earnings have been declining at an average annual rate of -25.3%, while the Healthcare industry saw earnings growing at 4.4% annually. Revenues have been declining at an average rate of 4.1% per year.

Key information

-25.3%

Earnings growth rate

-25.6%

EPS growth rate

Healthcare Industry Growth15.7%
Revenue growth rate-4.1%
Return on equityn/a
Net Margin-18.3%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Maternus-Kliniken makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:MAK Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 23102-1900
31 Mar 23105-1600
31 Dec 22107-1400
30 Sep 22108-1000
30 Jun 22110-600
31 Mar 22111-400
31 Dec 21111-300
30 Sep 21114-500
30 Jun 21116-700
31 Mar 21115-800
31 Dec 20114-1000
30 Sep 20116-1010
30 Jun 20117-1020
31 Mar 20121-1030
31 Dec 19124-1050
30 Sep 19125-760
30 Jun 19125-580
31 Mar 19125-3110
31 Dec 18124-2130
30 Sep 18125-2170
30 Jun 18126-2210
31 Mar 18126-2170
31 Dec 17127-1140
30 Sep 171270140
30 Jun 171262140
31 Mar 171251140
31 Dec 161241140
30 Sep 161244210
30 Jun 161242140
31 Mar 161242140
31 Dec 151232140
30 Sep 1512328140
30 Jun 1512428140
31 Mar 1512328140
31 Dec 1412227140
30 Sep 14120-9150
30 Jun 14118-10150
31 Mar 14115-11150
31 Dec 13114-13150
30 Sep 13113-12150
30 Jun 13113-10150

Quality Earnings: MAK is currently unprofitable.

Growing Profit Margin: MAK is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MAK is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.

Accelerating Growth: Unable to compare MAK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MAK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.5%).


Return on Equity

High ROE: MAK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.